Lispro
Insulin lispro is a rapid-acting insulin analogue used to control blood glucose levels in people with type 1 and type 2 diabetes mellitus. It works by replacing or supplementing the body’s insulin, promoting glucose uptake into muscle and fat cells while reducing glucose production by the liver. It is commonly available as subcutaneous injection solutions and prefilled insulin pens, and may also be administered through compatible insulin pumps or by intravenous infusion in selected clinical settings. It is generally administered shortly before or immediately after meals according to the prescribed treatment plan. The most common adverse effect is hypoglycaemia, while other possible effects include injection-site reactions, weight gain, and lipodystrophy. Blood glucose monitoring and appropriate dose adjustment are essential, particularly when meal intake, physical activity, or other diabetes medicines change.
Lispro was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Lispro, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Lispro from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Lispro, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
